Reference replicated designs [Regulatives / Guidelines]

posted by rajasekharkakarla – India, 2019-09-20 06:35 (330 d 09:21 ago) – Posting: # 20628
Views: 1,127

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar

Complete thread:

Activity
 Admin contact
21,027 posts in 4,382 threads, 1,460 registered users;
online 18 (0 registered, 18 guests [including 12 identified bots]).
Forum time: Saturday 15:56 CEST (Europe/Vienna)

It has yet to be proven
that intelligence has any survival value.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5